| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
Syros Pharmaceuticals, Inc. (SYRS) has 0 insiders with recent SEC Form 4 filings, including 13 buys and 3 sells. SYRS is classified in the Biotechnology industry within the Health Care sector.
| Role | Insider | Shares | Value | 30d |
|---|
Buys and sells only
| Date | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|
| Aug 7, 2017 | Olson Eric R | Chief Scientific Officer | Sale+OE | 2,500 | $23.59 | $58,969.00 | -100% | |
| Jul 25, 2017 | Olson Eric R | Chief Scientific Officer | Sale+OE | 12,500 | $21.85 | $273,125.00 | -100% | |
| Jul 25, 2017 | Young Richard A | Director | Sell | 3,282 | $22.09 | $72,495.77 | -0.8% | |
| Jul 6, 2016 | Arch Venture Fund VII LP | 10% Owner | Buy | 400,000 | $12.50 | $5,000,000.00 | +9.4% | |
| Jul 6, 2016 | Flynn James E62 | 10% Owner, Possible Members Of 10% Group | Buy | 400,000 | $12.50 | $5,000,000.00 | +23.6% | |
| Jul 6, 2016 | Nashat Amir | Director, 10% Owner | Buy | 400,000 | $12.50 | $5,000,000.00 | +33.7% | |
| Jul 6, 2016 | Redmile Group, LLC | 10% Owner | Buy | 432,746 | $12.50 | $5,409,325.00 | +113.5% | |
| Jul 6, 2016 | Nelsen Robert | Director, 10% Owner | Buy | 400,000 | $12.50 | $5,000,000.00 | +9.4% | |
| Jul 6, 2016 | Polaris Management Co. Vii, L.l.c. | 10% Owner | Buy | 400,000 | $12.50 | $5,000,000.00 | +33.7% | |
| Jul 6, 2016 | Aisling Capital III LP | 10% Owner | Buy | 400,000 | $12.50 | $5,000,000.00 | +78.7% |